Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews Sells 4,655 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) CFO Julie Andrews sold 4,655 shares of the firm’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the sale, the chief financial officer now directly owns 28,312 shares of the company’s stock, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Orthofix Medical Stock Performance

NASDAQ:OFIX opened at $18.36 on Wednesday. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25. The firm has a 50-day moving average price of $18.07 and a two-hundred day moving average price of $16.92. Orthofix Medical Inc. has a twelve month low of $12.08 and a twelve month high of $20.73. The company has a market capitalization of $701.54 million, a P/E ratio of -5.87 and a beta of 1.10.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings data on Thursday, November 7th. The medical device company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.57). The company had revenue of $196.61 million for the quarter, compared to analysts’ expectations of $196.60 million. Orthofix Medical had a negative return on equity of 21.25% and a negative net margin of 15.18%. During the same quarter in the prior year, the business posted ($0.77) EPS. As a group, research analysts expect that Orthofix Medical Inc. will post -2.81 earnings per share for the current fiscal year.

Institutional Trading of Orthofix Medical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. increased its stake in Orthofix Medical by 37.4% in the third quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company’s stock valued at $337,000 after purchasing an additional 5,702 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Orthofix Medical by 14.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 324,807 shares of the medical device company’s stock valued at $5,073,000 after buying an additional 39,901 shares during the period. AYAL Capital Advisors Ltd increased its stake in shares of Orthofix Medical by 10.2% during the 2nd quarter. AYAL Capital Advisors Ltd now owns 686,794 shares of the medical device company’s stock valued at $9,107,000 after acquiring an additional 63,697 shares during the last quarter. Barclays PLC lifted its holdings in shares of Orthofix Medical by 38.8% during the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 34,210 shares during the period. Finally, Paradigm Capital Management Inc. NY boosted its position in shares of Orthofix Medical by 31.3% in the second quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock worth $33,894,000 after acquiring an additional 609,137 shares during the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on OFIX shares. Stifel Nicolaus upgraded shares of Orthofix Medical from a “hold” rating to a “buy” rating and increased their price target for the company from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm reaffirmed a “buy” rating and issued a $22.00 target price (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, Orthofix Medical presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.